Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,

Indianapolis-based pharmaceutical giant Eli Lilly and Co. announced plans Wednesday to add four new manufacturing sites in a roughly $27 billion investment expected to create 3,000 jobs and nearly 10,000 construction positions during the buildout.